Norepinephrine

Evidence Level: L4

Predicted Indications: 3

Norepinephrine
1. Pharmacist Assessment Report
Norepinephrine: From Asthma and Obstructive Airway Disease to Obstructive Lung Disease

Pharmacist Assessment Report

Norepinephrine: From Asthma and Obstructive Airway Disease to Obstructive Lung Disease

One-Sentence Summary

Norepinephrine is an adrenergic agonist (a catecholamine) whose historical indications in the knowledge graph include asthma, bronchitis, emphysema, bronchiectasis and hypotensive disorders. The TxGNN model predicts it may be effective for obstructive lung disease, but only 1 clinical trial (graded low relevance) and 18 publications (mostly background reviews and physiology papers) were found, and none test norepinephrine as a treatment for this condition.

Quick Overview

Item	Content
Original Indication	Asthma, bronchitis, pulmonary emphysema, bronchiectasis, hypotensive disorder (from the knowledge graph; no approved indication text in the US license record)
Predicted New Indication	Obstructive lung disease
TxGNN Prediction Score	99.84%
Evidence Level	L4
US Market Status	Cancelled only
Number of NDAs	1 (cancelled)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available. Norepinephrine is known as an adrenergic agonist with predominantly alpha-1 activity. Its original indications in the knowledge graph (asthma, bronchitis, emphysema, bronchiectasis) are themselves obstructive airway diseases, so the prediction largely restates the historical label rather than offering new repurposing insight.

The literature does discuss adrenergic signalling and airway innervation in asthma and COPD, and neuroimmune mechanisms are plausible (PMID 29696025, 21271508, 41601146). However, systemic norepinephrine is a potent vasopressor and not a practical bronchodilator. The high TxGNN score is a computational prediction only and is not supported by clinical evidence for this use.

The other two predictions are weaker still. “Respiratory malformation” (score 99.84%) is supported only by preclinical work on noradrenergic control of breathing and by prenatal-exposure safety papers, which are not treatment evidence. “Rienhoff syndrome” (score 99.83%) has no trials and no literature, so no mechanistic link can be established.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02966665	Phase 1	Recruiting	420	Vascular function, exercise and skeletal muscle feedback in hypertension rehabilitation. It does not test norepinephrine for obstructive lung disease and provides no efficacy or safety evidence for this indication.

Literature Evidence

No randomized trials were found. The retrieved publications are reviews and physiological or observational studies, listed here by relevance.

PMID	Year	Type	Journal	Key Findings
29696025	2018	Review	Front Immunol	Adrenergic signalling at the interface of allergic asthma and viral infections
41601146	2026	Review	Ann Med	Neuroimmune circuits in respiratory disease and potential therapeutic targets
21271508	2011	Review	Pneumologie	Airway innervation in asthma and COPD, including sympathetic norepinephrine signalling
24486056	2014	Review	Semin Immunol	Neuroendocrine regulation of inflammation by the sympathetic nervous system
3332227	1987	Review	Crit Care Clin	Catecholamines (norepinephrine, epinephrine, dopamine) in critical care
40870471	2025	Review	Medicina (Kaunas)	Anxiety and depression as comorbidities of COPD
3966494	1985	Physiological study	Am J Med	Effect of hypoxemia on sodium and water excretion in advanced COPD (11 patients)
29030339	2018	Physiological study	Am J Physiol Heart Circ Physiol	Muscle alpha-adrenergic responsiveness during exercise in COPD patients
35870527	2022	Panel study	Environ Pollut	Stress hormones and air pollution exposure in COPD and non-COPD participants
11099681	2000	Clinical study	Am J Med	Mechanisms of hypertension in COPD with acute respiratory failure, including norepinephrine levels

US Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
No number recorded (cancelled)	Norepinephrine (BioActive Nutritional, Inc.)	Liquid	No approved indication text recorded

Safety Considerations

Knowledge-graph contraindications: hypertensive disorder, hypertension and thrombotic disease. These come from the knowledge graph and not from label text.
Drug Interactions: 70 interactions were identified, all or mostly of Moderate severity. Examples include antidiabetic agents (metformin, sitagliptin, pioglitazone, canagliflozin, dapagliflozin, empagliflozin, semaglutide, insulins), as well as phentermine and diethylpropion.

Please refer to the package insert for key warnings and the full contraindication list, as label data was not available for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The only clinical trial found is a Phase 1 hypertension study unrelated to this indication, and the literature consists of background reviews and physiology papers. The high TxGNN score is a computational prediction, the mechanistic overlap mostly restates the old label, and the only US product record is cancelled. Systemic norepinephrine is a vasopressor rather than a practical bronchodilator, and the knowledge-graph contraindications include hypertension and thrombotic disease.

To proceed, the following is needed:

FDA package insert warnings and contraindications (a blocking gap for safety screening)
Mechanism of action data (for example from DrugBank)
Clinical or well-designed preclinical evidence that norepinephrine, by a feasible route and dose, benefits obstructive lung disease
Route and formulation compatibility assessment, since no suitable active US product is available
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.